Taurine is an amino sulfonic acid that has garnered interest in recent years for its potential neuroprotective effects, including in the context of Alzheimer's Disease (AD). Preclinical studies, primarily in vitro and in animal models, have suggested that taurine may exert beneficial effects on the brain by modulating neurotransmission, reducing oxidative stress, and inhibiting amyloid-β aggregation, which is a hallmark of AD pathology. For example, some studies in AD mouse models have reported that taurine supplementation can improve cognitive performance and reduce amyloid pathology. Proposed mechanisms include taurine’s antioxidant properties, its ability to regulate intracellular calcium homeostasis, and its anti-inflammatory effects.

However, robust clinical evidence in humans is lacking. There have been very few, if any, well-powered randomized controlled trials evaluating taurine supplementation in AD patients. Most of the supporting data come from animal studies or cell cultures, and while promising, these findings do not directly translate to proven efficacy in humans with Alzheimer's Disease. As such, taurine is not a widely accepted or standard treatment for AD, but it is sometimes mentioned in the scientific literature as a candidate for further research. In summary, the scientific rationale exists largely at the preclinical level, and current human evidence is insufficient to strongly support taurine’s use for AD beyond experimental or adjunctive contexts.